Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Brian Hill
- Target Recruit Count
- 19
- Registration Number
- NCT02898259
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 46
- Registration Number
- NCT02897830
- Locations
- 🇫🇷
University Hosptial Toulouse, Toulouse, France
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
- Conditions
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 124
- Registration Number
- NCT02891811
- Locations
- 🇦🇹
Bezirkskrankenhaus Kufstein, Innere Medizin, Interne II u. onkologische Tagesklinik, Kufstein, Austria
🇦🇹Univ.Klinikum Krems, Klin. Abt. f. Innere Medizin 2, Mitterweng, Austria
🇦🇹Ordensklinikum Linz - Elisabethinen, I. Interne Abt. Haemato-Onkologie, Linz, Austria
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
- Conditions
- Interventions
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02886065
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Massachusetts general Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 11
- Registration Number
- NCT02880228
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 6
- Registration Number
- NCT02875067
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸NYU Perlmutter Cancer Center, New York, New York, United States
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 224
- Registration Number
- NCT02874742
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 96
- Registration Number
- NCT02871219
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Early Patient Access Treatment Use Protocol CA204-220
- Conditions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT02856438
- Locations
- 🇯🇵
Local Institution, Osaka-shi, Osaka, Japan
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2016-07-25
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 53
- Registration Number
- NCT02843074
- Locations
- 🇺🇸
HCA Midwest Health/Research Medical Center, Kansas City, Missouri, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.